Nobutaka Hattori

Wako, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 907 publications

α-Synuclein burden amplification in Parkinson's disease: a unified genetic, molecular, and cellular framework.

α-Synuclein burden amplification in Parkinson's disease: a unified genetic, molecular, and cellular framework.

Journal: Frontiers in neurology
Published: July 01, 2026

Levodopa-induced alterations in vertical center of mass and muscle synergy structure during Parkinsonian gait.

Levodopa-induced alterations in vertical center of mass and muscle synergy structure during Parkinsonian gait.

Journal: Experimental brain research
Published: April 30, 2026

Astrocyte-Predominant Tau Pathology in a Patient With VCP R191Q Variant.

Astrocyte-Predominant Tau Pathology in a Patient With VCP R191Q Variant.

Journal: Neuropathology : official journal of the Japanese Society of Neuropathology
Published: April 29, 2026

Generation of hiPSCs (JUCGRMi008-A) from a β-propeller protein-associated neurodegeneration patient with WDR45 mutation.

Generation of hiPSCs (JUCGRMi008-A) from a β-propeller protein-associated neurodegeneration patient with WDR45 mutation.

Journal: Stem cell research
Published: April 10, 2026

Exploration of the longitudinal clinical course and potential prognostic factors in Parkinson's disease: 2.5-year observational study in Japan.

Exploration of the longitudinal clinical course and potential prognostic factors in Parkinson's disease: 2.5-year observational study in Japan.

Journal: Frontiers in neurology
Published: April 02, 2026

Deep brain stimulation in VPS13C-associated Parkinson's disease: a longitudinal case study.

Deep brain stimulation in VPS13C-associated Parkinson's disease: a longitudinal case study.

Journal: Clinical parkinsonism & related disorders
Published: March 18, 2026

Impact of catechol-O-methyltransferase inhibition on plasma homocysteine levels in levodopa-treated Parkinson's disease.

Impact of catechol-O-methyltransferase inhibition on plasma homocysteine levels in levodopa-treated Parkinson's disease.

Journal: Journal of neural transmission (Vienna, Austria : 1996)
Published: March 11, 2026

A Low LDL-C Level but not Statin Use is Associated with In-hospital Mortality in Spontaneous Intracerebral Hemorrhage; The J-ICH Registry.

A Low LDL-C Level but not Statin Use is Associated with In-hospital Mortality in Spontaneous Intracerebral Hemorrhage; The J-ICH Registry.

Journal: Journal of atherosclerosis and thrombosis
Published: March 08, 2026

Detecting the seeds of Parkinson's disease: the evolution of α‑synuclein seed amplification assay as a clinical biomarker.

Detecting the seeds of Parkinson's disease: the evolution of α‑synuclein seed amplification assay as a clinical biomarker.

Journal: Journal of neural transmission (Vienna, Austria : 1996)
Published: February 27, 2026

Real-world outcomes and early discontinuation of foslevodopa/foscarbidopa in Parkinson's disease.

Real-world outcomes and early discontinuation of foslevodopa/foscarbidopa in Parkinson's disease.

Journal: Journal of neurology
Published: February 25, 2026

A PARK9 iPSC-Derived Dopaminergic Neuron Model Enables Drug Screening Targeting Autophagy-Lysosome Pathway Dysfunction in Parkinson's Disease.

A PARK9 iPSC-Derived Dopaminergic Neuron Model Enables Drug Screening Targeting Autophagy-Lysosome Pathway Dysfunction in Parkinson's Disease.

Journal: Journal of neurochemistry
Published: January 30, 2026

Genetic variation in antidiabetic drug targets: associations with Parkinson's disease risk and age at onset.

Genetic variation in antidiabetic drug targets: associations with Parkinson's disease risk and age at onset.

Journal: NPJ Parkinson's disease
Published: January 20, 2026
Showing 1-12 of 907

Last Updated: 09/26/2026